Home › Mycosis Fungoides › NCT02848274
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients With Advanced Mycosis Fungoides and Sézary Syndrome
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria * Diagnosis of advanced stage MF or SS (Stages IIB - IVB) within 6 months of presentation to the participating center * Patients that are expected to have care administered at the participating center or jointly with referring physician(s) where follow-up data would be available Exclusion Criteria * Patients diagnosed with early stage MF/SS (Stages IA-IIA) before progressing to advanced stage * Patients diagnosed with advanced MF/SS more than 6 months prior to initial presentation to the participating center * Exclude one-time consultation type of new patients.
About the study
The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.
Sponsor: Stanford University · Participants: 2,000 · Started: 2016-10
Contact the study team
- Tatiana Neal · Phone: 650-709-7838
Official record on ClinicalTrials.gov — NCT02848274
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.